Abstract:The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here Background: Benign prostatic hyperplasia (BPH) is a common issue among older men. Diagnosis of BPH currently relies on imaging tests and assessment of urinary flow rate due to the absence of definitive diagnostic markers. Developing more accurate markers is crucial to improve BPH diagnosis.The BPH dataset utilized in this study was sourced from the Gene Expression Omnibus (GEO). Initially, differential expression and functional analyses were conducted, followed by the application of multiple machine learning techniques to identify key diagnostic markers. Subsequent investigations have focused on elucidating the functions and mechanisms associated with these markers. The ssGSEA method was employed to evaluate immune cell scores in BPH samples, facilitating the exploration of the relationship between key diagnostic markers and immune cells. Additionally, molecular docking was performed to assess the binding affinity of these key markers to therapeutic drugs for BPH. Tissue samples from BPH patients were collected for experimental validation of the expression differences of the aforementioned genes.Result: A total of 185 differential genes were identified, comprising 67 up-regulated and 118 down-regulated genes. These genes are implicated in pathways that regulate extracellular matrix tissue composition and cellular responses to transforming growth factor beta stimulation, as well as critical signaling pathways such as AMPK and mTOR. Through the application of various machine learning techniques, DACH1, CACNA1D, STARD13, and RUNDC3B were identified as key diagnostic markers. The ssGSEA algorithm further corroborated the association of these diagnostic genes with diverse immune cells. Moreover, molecular docking analysis revealed strong binding affinities of these markers to tamsulosin and finasteride, suggesting their potential as drug targets. Finally, experimental validation confirmed the expression differences of DACH1, CACNA1D, STARD13, and RUNDC3B in BPH tissues.This study introduces novel immune-related diagnostic markers for BPH and highlights their promise as new drug targets, providing a valuable approach for predictive diagnosis and targeted therapy of BPH.

Correlation Between Molecular Biomarkers and Risk Factors for the Clinical Progression of Benign Prostatic Hyperplasia Using Tissue Micro Array Immuno Staining

THE RELATIONSHIP OF THE PROLIFERATION AND PHENOTYPIC MODULATION OF THE STROMAL CELLS AND THE EXPRESSION OF ESTROGEN RECEPTOR α IN BENIGN PROSTATIC HYPERPLASIA

Relationship between the Expression of Estrogen Receptor α and Basal Cell Dedifferentiation in Benign Prostatic Hyperplasia

Clinical Relevance And Implications Of Autophagy-Related Proteins In Benign Prostatic Hyperplasia

Prostate-specific antigen, androgen, progesterone and oestrogen receptors in Benign prostatic hyperplasia: human tissues and animal model study

Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia

Expressions of Shh and Stathmin in Prostatic Diseases and Their Clinical Significances

Expression of Ki-67, Bcl-2, Bax and Caspase-3 in Benign Prostatic Hyperplasia Combined with Prostatitis and Their Significances

A Retrospective Study: Correlation of Histologic Inflammation in Biopsy Specimens of Chinese Men Undergoing Surgery for Benign Prostatic Hyperplasia with Serum Prostate-Specific Antigen.

Predictive Factors for Tissue Inflammation in Patients with Benign Prostatic Hyperplasia: A Clinical Prediction Study

Correlation of Prostatic Morphological Parameters and Clinical Progression in Aging Chinese Men with Benign Prostatic Hyperplasia: Results from a Cross-Sectional Study.

Study on Expression of PTEN/MMAC1/TEP1,TGF-β1 and Their Biological Significance in Benign Prostatic Hyperplasia and Prostatic Cancer

The expressions and clinical significances of AR in prostate carcinoma

Immune-related diagnostic markers for benign prostatic hyperplasia and their potential as drug targets

CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer

Correlation between clinical prameter and histology of BPH

Increased expressions of VEGF and VEGF-C in prostate cancer tissue are associated with tumor progression

Differential Research of Inflammatory and Related Mediators in BPH, Histological Prostatitis and PCa.

Apoptosis Profiles in Benign Prostatic Hyperplasia: Close Associations of Cell Kinetics with Percent Area Density of Histologic Composition.

Correlations of Immune Inflammation with Total Prostate Volume and Androgen Receptor Expression

Mitogen-Activated Protein Kinase Pathway and Four Genes Involved in the Development of Benign Prostatic Hyperplasia: <i>In Vivo</i> and <i>Vitro</i> Validation